| Chronic graft-versus-host disease
Niktimvo vs Rezurock
Side-by-side clinical, coverage, and cost comparison for chronic graft-versus-host disease.Deep comparison between: Niktimvo vs Rezurock with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRezurock has a higher rate of injection site reactions vs Niktimvo based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Rezurock but not Niktimvo, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Niktimvo
Rezurock
At A Glance
IV infusion
Every 2 weeks
CSF-1R antagonist
Oral
Daily
ROCK2 inhibitor
Indications
- Chronic graft-versus-host disease
- Chronic graft-versus-host disease
Dosing
Chronic graft-versus-host disease 0.3 mg/kg (maximum 35 mg) as an intravenous infusion over 30 minutes every 2 weeks until progression or unacceptable toxicity; for patients weighing at least 40 kg.
Chronic graft-versus-host disease 200 mg orally once daily with food until progression of chronic GVHD requiring new systemic therapy; increase to 200 mg twice daily when coadministered with strong CYP3A inducers or proton pump inhibitors.
Contraindications
—
—
Adverse Reactions
Most common (>=15%) Increased AST, infection (pathogen unspecified), increased ALT, decreased phosphate, decreased hemoglobin, viral infection, increased GGT, musculoskeletal pain, increased lipase, fatigue, increased amylase, increased calcium, increased CPK, increased ALP, nausea, headache, diarrhea, cough, bacterial infection, pyrexia, dyspnea
Serious Infection (pathogen unspecified), viral infection, respiratory failure
Most common (>=20%) Infections, asthenia, nausea, diarrhea, dyspnea, cough, edema, hemorrhage, abdominal pain, musculoskeletal pain, headache, phosphate decreased, gamma glutamyl transferase increased, lymphocytes decreased, hypertension
Pharmacology
Axatilimab-csfr is a CSF-1R antagonist; a monoclonal antibody that binds to colony stimulating factor-1 receptors (CSF-1R) on monocytes and macrophages, reducing circulating proinflammatory and profibrotic monocytes and monocyte-derived macrophages, and inhibiting the activity of pathogenic macrophages in tissues.
Belumosudil is a ROCK inhibitor that selectively inhibits ROCK2 (IC50 approximately 100 nM) and ROCK1 (IC50 approximately 3 uM), down-regulating proinflammatory STAT3/STAT5 signaling and Th17/Treg imbalance while inhibiting pro-fibrotic signaling implicated in chronic GVHD.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Niktimvo
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
Rezurock
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (11/12) · Qty limit (9/12)
UnitedHealthcare
Niktimvo
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Rezurock
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (4/8) · Qty limit (1/8)
Humana
Niktimvo
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (0/3)
Rezurock
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$15/fillfill
IncyteCARES for Niktimvo Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
$10/momo
Kadmon ASSIST Copay Savings Card: RezurockCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
NiktimvoView full Niktimvo profile
RezurockView full Rezurock profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.